- Home
- JHI vs VERU Comparison
JHI vs VERU Comparison
Compare JHI & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- VERU
- Stock Information
- Founded
- JHI 1971
- VERU 1971
- Country
- JHI United States
- VERU United States
- Employees
- JHI N/A
- VERU N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- VERU Health Care
- Exchange
- JHI Nasdaq
- VERU Nasdaq
- Market Cap
- JHI 124.3M
- VERU 108.8M
- IPO Year
- JHI N/A
- VERU 1990
- Fundamental
- Price
- JHI $14.09
- VERU $1.09
- Analyst Decision
- JHI
- VERU Strong Buy
- Analyst Count
- JHI 0
- VERU 4
- Target Price
- JHI N/A
- VERU $4.00
- AVG Volume (30 Days)
- JHI 29.5K
- VERU 2.4M
- Earning Date
- JHI 01-01-0001
- VERU 02-06-2025
- Dividend Yield
- JHI 6.80%
- VERU N/A
- EPS Growth
- JHI N/A
- VERU N/A
- EPS
- JHI 1.05
- VERU N/A
- Revenue
- JHI N/A
- VERU $16,886,419.00
- Revenue This Year
- JHI N/A
- VERU N/A
- Revenue Next Year
- JHI N/A
- VERU N/A
- P/E Ratio
- JHI $12.47
- VERU N/A
- Revenue Growth
- JHI N/A
- VERU 3.62
- 52 Week Low
- JHI $11.63
- VERU $0.36
- 52 Week High
- JHI $13.40
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- JHI 57.83
- VERU 79.55
- Support Level
- JHI $13.84
- VERU $0.70
- Resistance Level
- JHI $14.17
- VERU $0.81
- Average True Range (ATR)
- JHI 0.11
- VERU 0.11
- MACD
- JHI 0.04
- VERU 0.04
- Stochastic Oscillator
- JHI 84.62
- VERU 83.64
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.